Quantity of eligible individuals: CDEC mentioned the uncertainty in the number of people with moderately critical to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some individuals who are categorized as obtaining delicate or average disease could possibly have a serious bleeding https://hemgenix19361.tribunablog.com/everything-about-hemgenix-50145125